Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20230942 | 1.00 | GNAI3 (0.47) | GNAI3GNAO1GNAI1LTA4HHRH2 | |
| SCHEMBL21477155 | 0.91 | GNAI3 (0.40) | GNAI3GNAO1GNAI1LTA4HHRH2 | |
| SCHEMBL22520691 | 0.89 | KDM4E (0.40) | GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL22520687 | 0.87 | ALDH1A1 (0.46) | GNAI3GNAO1GNAI1KDM4ETHRA | |
| SCHEMBL29325698 | 0.87 | ALDH1A1 (0.46) | GNAI3GNAO1GNAI1KDM4ETHRA | |
| SCHEMBL21421563 | 0.87 | GNAI3 (0.48) | GNAI3GNAO1GNAI1LTA4HKDM4E | |
| SCHEMBL12228112 | 0.85 | ALDH1A1 (0.47) | KDM4E | |
| SCHEMBL26741730 | 0.84 | MEN1 (0.41) | HRH2HRH1 | |
| SCHEMBL22520630 | 0.84 | MAOB (0.47) | GNAI3GNAO1GNAI1 | |
| SCHEMBL26712202 | 0.84 | MAOB (0.47) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | BAZ2A, BRD3, BRPF3 | GNAI3 618/4885GNAO1 2309/4885GNAI1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.